TIDMAREC

RNS Number : 2300B

Arecor Therapeutics PLC

09 June 2021

Arecor Therapeutics plc

("Arecor", the "Company" or the "Group")

Director Dealing

Cambridge, UK, 9(th) June 2021. Arecor Therapeutics plc (AIM: AREC) , the biopharmaceutical company advancing today's therapies to enable healthier lives, today announces the following Directors' dealings:

Dr Andrew Richards, Non-Executive Chairman, purchased 12,500 ordinary shares of GBP0.01 each in the capital of the Company ("Ordinary Shares") at a price of 242.7 pence per Ordinary Share.

Christine Soden, Non-Executive Director, purchased 12,500 Ordinary Shares at a price of 242.7 pence per Ordinary Share.

Jeremy Morgan, Non-Executive Director, purchased 20,503 Ordinary Shares at a price of 242.5 pence per Ordinary Share.

Following the transactions, the total beneficial interest of Dr Andrew Richards is 217,168 Ordinary Shares, representing 0.78% of the total voting rights, the total beneficial interest of Christine Soden is 12,500 Ordinary Shares, representing 0.05% of the total voting rights and the total beneficial interest of Jeremy Morgan is 20,503 Ordinary Shares, representing 0.07% of the total voting rights.

-S-

For more information, please contact:

 
 Arecor Therapeutics plc                  www.arecor.com 
 Dr Sarah Howell, Chief Executive         Tel: +44 (0) 1223 426060 
  Officer                                  Email: info@arecor.com 
 
 Susan Lowther, Chief Financial Officer   Tel: +44 (0) 1223 426060 
                                           Email: info@arecor.com 
 
 Mo Noonan, Communications                Tel: +44 (0) 7876 444977 
                                           Email: mo.noonan@arecor.com 
 
 Panmure Gordon (UK) Limited (NOMAD       Tel: +44 (0) 20 7886 2500 
  and Broker) 
  Freddy Crossley, Emma Earl (Corporate 
  Finance) 
  Rupert Dearden (Corporate Broking) 
 
 Consilium Strategic Communications 
 Chris Gardner, David Daley, Angela       Tel: +44 (0) 20 3709 5700 
  Gray                                     Email: arecor@consilium-comms.com

Notes to Editors

About Arecor

Arecor Therapeutics plc is a biopharmaceutical company transforming patient care by bringing innovative medicines to market. Through the enhancement of existing medicines using our Arestat(TM) technology, we are developing a broad portfolio of therapies as part of our proprietary pipeline and through partnerships with leading pharmaceutical and biotech companies. Our treatments for people living with chronic disease are designed to simplify patient care and improve medication adherence.

For further details please see our website, www.arecor.com

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING

MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 
        Details of the person discharging managerial responsibilities/person 
    1    closely associated 
 a)     Name                             Andrew Richards 
       -------------------------------  ---------------------------------------- 
 2      Reason for the notification 
       ------------------------------------------------------------------------- 
 a)     Position/status                  Non-Executive Chairman 
       -------------------------------  ---------------------------------------- 
 b)     Initial notification/Amendment   Initial notification 
       -------------------------------  ---------------------------------------- 
 3      Details of the issuer, emission allowance market participant, 
         auction platform, auctioneer or auction monitor 
       ------------------------------------------------------------------------- 
 a)     Name                             Arecor Therapeutics plc 
       -------------------------------  ---------------------------------------- 
 b)     LEI                              98450093D12I3A8DDD58 
       -------------------------------  ---------------------------------------- 
 4      Details of the transaction(s): section to be repeated for (i) 
         each type of instrument; (ii) each type of transaction; (iii) 
         each date; and (iv) each place where transactions have been 
         conducted 
       ------------------------------------------------------------------------- 
 a)     Description of the               Ordinary Shares 
         financial instrument, 
         type of instrument 
       -------------------------------  ---------------------------------------- 
 b)     Identification Code              GB00BMWLM973 
       -------------------------------  ---------------------------------------- 
 c)     Nature of the transaction        Purchase of shares 
       -------------------------------  ---------------------------------------- 
 
 d)     Price(s) and volume(s)            242.7 pence and 12,500 Ordinary Shares 
       -------------------------------  ---------------------------------------- 
 e)     Aggregated information 
         - Aggregated volume 
         - Aggregated price 
       -------------------------------  ---------------------------------------- 
 f)     Date of the transaction          8 June 2021 
       -------------------------------  ---------------------------------------- 
 g)     Place of the transaction         London Stock Exchange, AIM 
       -------------------------------  ---------------------------------------- 
 
 
        Details of the person discharging managerial responsibilities/person 
    1    closely associated 
 a)     Name                             Christine Soden 
       -------------------------------  ---------------------------------------- 
 2      Reason for the notification 
       ------------------------------------------------------------------------- 
 a)     Position/status                  Non-Executive Director 
       -------------------------------  ---------------------------------------- 
 b)     Initial notification/Amendment   Initial notification 
       -------------------------------  ---------------------------------------- 
 3      Details of the issuer, emission allowance market participant, 
         auction platform, auctioneer or auction monitor 
       ------------------------------------------------------------------------- 
 a)     Name                             Arecor Therapeutics plc 
       -------------------------------  ---------------------------------------- 
 b)     LEI                              98450093D12I3A8DDD58 
       -------------------------------  ---------------------------------------- 
 4      Details of the transaction(s): section to be repeated for (i) 
         each type of instrument; (ii) each type of transaction; (iii) 
         each date; and (iv) each place where transactions have been 
         conducted 
       ------------------------------------------------------------------------- 
 a)     Description of the               Ordinary Shares 
         financial instrument, 
         type of instrument 
       -------------------------------  ---------------------------------------- 
 b)     Identification Code              GB00BMWLM973 
       -------------------------------  ---------------------------------------- 
 c)     Nature of the transaction        Purchase of shares 
       -------------------------------  ---------------------------------------- 
 
 d)     Price(s) and volume(s)            242.7 pence and 12,500 Ordinary Shares 
       -------------------------------  ---------------------------------------- 
 e)     Aggregated information 
         - Aggregated volume 
         - Aggregated price 
       -------------------------------  ---------------------------------------- 
 f)     Date of the transaction          8 June 2021 
       -------------------------------  ---------------------------------------- 
 g)     Place of the transaction         London Stock Exchange, AIM 
       -------------------------------  ---------------------------------------- 
 
 
   1   Details of the person discharging managerial responsibilities/person 
        closely associated 
 a)    Name                             Jeremy Morgan 
      -------------------------------  ---------------------------------------- 
 2     Reason for the notification 
      ------------------------------------------------------------------------- 
 a)    Position/status                  Non-Executive Director 
      -------------------------------  ---------------------------------------- 
 b)    Initial notification/Amendment   Initial notification 
      -------------------------------  ---------------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      ------------------------------------------------------------------------- 
 a)    Name                             Arecor Therapeutics plc 
      -------------------------------  ---------------------------------------- 
 b)    LEI                              98450093D12I3A8DDD58 
      -------------------------------  ---------------------------------------- 
 4     Details of the transaction(s): section to be repeated for (i) 
        each type of instrument; (ii) each type of transaction; (iii) 
        each date; and (iv) each place where transactions have been 
        conducted 
      ------------------------------------------------------------------------- 
 a)    Description of the               Ordinary Shares 
        financial instrument, 
        type of instrument 
      -------------------------------  ---------------------------------------- 
 b)    Identification Code              GB00BMWLM973 
      -------------------------------  ---------------------------------------- 
 c)    Nature of the transaction        Purchase of shares 
      -------------------------------  ---------------------------------------- 
 
 d)    Price(s) and volume(s)            242.5 pence and 20,503 Ordinary Shares 
      -------------------------------  ---------------------------------------- 
 e)    Aggregated information 
        - Aggregated volume 

        - Aggregated price 
      -------------------------------  ---------------------------------------- 
 f)    Date of the transaction          8 June 2021 
      -------------------------------  ---------------------------------------- 
 g)    Place of the transaction         London Stock Exchange, AIM 
      -------------------------------  ----------------------------------------

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBLGDLUXGDGBI

(END) Dow Jones Newswires

June 09, 2021 02:00 ET (06:00 GMT)

Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Arecor Therapeutics Charts.
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Arecor Therapeutics Charts.